Why did MEDS stock jump? — 2026-11-20

Research session: 2026-11-20. Published: 2026-11-20T21:33:41.809888+00:00.

Final report

MEDS — DataMeds AI, Inc. - Common Stock

Session close: $1.34. Regular-session share volume: 58,136,856. Change from previous close: +84.14%.

Key developments

DataMeds AI agreed to acquire the TBIA cancer AI blood test platform from the Todos Medical estate for its subsidiary Helomics, a certified cancer diagnostics laboratory. The spectroscopy platform previously held European regulatory marks for breast and colorectal cancer tests. Helomics plans to revalidate data correlations with biopsies and imaging and support a lab-developed test launch ahead of regulatory submissions. Issued patents in the United States and Europe are described as providing exclusivity well into the next decade.

Company news DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.

News sources

Company news DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.

Full report for 2026-11-20